Conference Announcement

 


We are here to announce our prestigious event " 24th Annual Meet on Obesity and Diet" scheduled on March 13-14, 2023 in London, UK. This event will have a mix of lectures of keynote addresses, panel discussions, case discussions, current reports of scientific progress featured in oral abstracts and posters. This conference offers an opportunity for faculty, postgraduates, fellows, residents, and undergraduates to present their work, learn and network with the experts on Obesity.

Comments

Post a Comment

Popular posts from this blog

Obesity and Cancer

Image
                     Obesity and Cancer Is obesity a cause for  cancer? Is that mean more cells equal more chances to cancer!!! Worldwide 1.1 billion people are currently estimated to be overweight, at least 300 million of them obese. Worldwide, cancer affects roughly 22 million persons who are living with the condition. This makes it a major public health problem. The prevalence of excess body weight and obesity is rapidly increasing worldwide. Apart from several conditions like diabetes, heart disease, liver and gall bladder disorders, cancers have also been associated with obesity. There is sufficient evidence to link certain forms of cancers to obesity. Association between cancers and obesity The International Agency for Research on Cancer has assessed the association between cancers and obesity. Their focus was on certain cancers like cancers of the colon, female breast (especially in women who have achieved menopause), e...
Read more

Eli Lily, a pharmaceutical giant to release a diabetes drug.

Image
Eli Lily, a pharmaceutical giant to release a  diabetes drug. Pharmaceutical giant Eli Lilly said Thursday it will seek approval to add its diabetes drug to the buzzy US weight loss market after achieving promising results in a new clinical trial Tirzepatide, currently approved to treat type 2 diabetes under the name Mounjaro, is taken once a week as an injection.  Eli Lilly said its trial was conducted over a period of 72 weeks on just over 900 overweight or obese participants with type 2 diabetes. Those who received the highest dosage lost an average of 15.7 percent of their body weight, or 34.4 pounds (15.6 kilograms), the company said, with the most common side effects being mild to moderate gastrointestinal issues such as nausea and diarrhea. Like other drugs which have recently become popular for weight loss, tirzepatide mimics the gastrointestinal hormone GLP-1, activating receptors in the brain involved in appetite regulation. Though Mounjaro has only been approved in ...
Read more